Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways

August 28th 2024

The panel evaluates selinexor's current role in the treatment landscape for multiple myeloma and explores its potential future applications and evolving significance in therapeutic strategies.

Overview of CAR T-cell Therapy Options in R/R MM

August 28th 2024

The experts examine the available CAR T-cell therapy options for relapsed/refractory multiple myeloma.

Bispecific Antibody De-Escalation: Varying Dosing Strategies Aim to Improve Safety, Maintain Efficacy in R/R Myeloma

August 27th 2024

Rahul Banerjee MD, FACP, discusses various dosing strategies and schedules for bispecific antibodies in multiple myeloma.

Dr Sonneveld on the Background of the D-VRd Regimen in Newly Diagnosed Myeloma

August 27th 2024

Pieter Sonneveld, MD, PhD, discusses the background of the PERSEUS trial, which evaluated D-VRd for induction and consolidation in newly diagnosed myeloma.

Time-Limited Bispecific Antibodies Could Represent Next Shift in Myeloma Treatment

August 26th 2024

Rahul Banerjee MD, FACP, discusses the rapidly evolving therapeutic landscape of bispecific antibodies in the treatment of patients with multiple myeloma.

DREAMM-7 and DREAMM-8 Data Support Belantamab Mafodotin–Based Combos in R/R Myeloma

August 24th 2024

Suzanne Trudel, MSc, MD, discusses updated data from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin–based regimens in R/R multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 8/18

August 24th 2024

A frontline doublet receives FDA approval in EGFR+ NSCLC, a CRL is issued to linvoseltamab in multiple myeloma, and more this week from OncLive.

Dr Krishnan on the Role of Cilta-Cel in High-Risk Multiple Myeloma

August 23rd 2024

Amrita Krishnan, MD, discusses the potential role for cilta-cel in early-relapsed, high-risk patients with multiple myeloma.

Dr Sonneveld on the Potential of Quadruplet Therapy Regimens in Multiple Myeloma

August 22nd 2024

Pieter Sonneveld, MD, PhD, discusses the potential of quadruplet therapeutic regimens in the frontline management of multiple myeloma.

Dr Mohty on the Potential Role of BCMA-Targeted Bispecific Antibodies in Myeloma

August 22nd 2024

Mohamad Mohty, MD, PhD, discusses the potential role of BCMA-targeted bispecific antibodies in myeloma.

FDA Issues Complete Response Letter to Linvoseltamab BLA in R/R Multiple Myeloma

August 21st 2024

The FDA has issued a CRL to the BLA seeking approval of linvoseltamab for use in select patients with relapsed or refractory multiple myeloma.

Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM

August 21st 2024

The panelists explore the evolution of treatment approaches for patients with relapsed/refractory multiple myeloma who have undergone 1-3 lines of therapy, with a particular focus on the implications of increased anti-CD38 monoclonal antibody usage in newly diagnosed or early relapse cases.

Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens

August 21st 2024

The key opinion leaders examine selinexor combinations and dosing strategies they currently employ, while also addressing how the frequency of treatment-related adverse events (TRAEs) associated with selinexor varies with lower dosing regimens in the context of managing early relapse multiple myeloma.

Dr Sonneveld on the FDA Approval of Subcutaneous Daratumumab Plus VRd in Myeloma

August 20th 2024

Pieter Sonneveld, MD, PhD, discusses the FDA approval of daratumumab plus VRd for select patients with newly diagnosed multiple myeloma.

Dr Hernandez-Ilizaliturri on the Use of CAR T-Cell Therapy in R/R Multiple Myeloma

August 19th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Dr Banerjee on Selecting Between Bispecific and CAR T-Cell Treatments in Myeloma

August 16th 2024

Rahul Banerjee, MD, FACP, discusses factors that may inform treatment selection when choosing between bispecific antibodies and CAR T-cell therapies in multiple myeloma

Linvoseltamab Demonstrates Deep, Durable Responses in R/R Myeloma Ahead of FDA Action Date

August 15th 2024

Suzanne Lentzsch, MD, PhD, discusses updated data from the LINKER-MM1 study of linvoseltamab in relapsed/refractory multiple myeloma.

Dr Trudel on the Significance of the DREAMM-7 and DREAMM-8 Trials in R/R Multiple Myeloma

August 15th 2024

Suzanne Trudel, MSc, MD, discusses the implications of results from the DREAMM-7 and DREAMM-8 trials in relapsed/refractory multiple myeloma.

Clinical Insights on Next Treatment Approach Steps

August 14th 2024

A panel of experts in relapsed/refractory multiple myeloma analyzes a patient case, detailing their clinical approach to optimize outcomes for a 68-year-old male presenting with early relapse multiple myeloma.

Clinical Scenario I: 68-yr Old Man with Early Relapse MM

August 14th 2024

Key opinion leaders present a clinical patient scenario involving a 68-year-old male patient presenting with early relapse multiple myeloma.